NCT06980077 is a Phase 2 clinical trial of Biopsy Procedure in Thymus Carcinoma, sponsored by Jonsson Comprehensive Cancer Center.

Who is sponsoring NCT06980077?

NCT06980077 is sponsored by Jonsson Comprehensive Cancer Center.

What drugs are being tested in NCT06980077?

Interventions in NCT06980077: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ivonescimab, Magnetic Resonance Imaging, Questionnaire Administration.

What condition does NCT06980077 study?

NCT06980077 studies Thymus Carcinoma.

Is NCT06980077 still recruiting?

NCT06980077 is currently recruiting now. Last updated 20 October 2025.

Last reviewed 2025-10-20 · How we verify

NCT06980077

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ivonescimab for the Treatment of Thymic Cancer

Recruiting now Phase 2 Last updated 20 October 2025

What this trial tests

Phase 2 trial testing Biopsy Procedure in Thymus Carcinoma in 25 participants. Currently enrolling.

Timeline

15 July 2025

Primary endpoint
17 June 2027

17 June 2028

Quick facts

Lead sponsor	Jonsson Comprehensive Cancer Center
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	15 July 2025
Primary completion	17 June 2027
Estimated completion	17 June 2028
Sites	1 location across United States

Drugs / interventions tested

Biopsy Procedure
Biospecimen Collection — full drug profile →
Computed Tomography
Ivonescimab — full drug profile →
Magnetic Resonance Imaging
Questionnaire Administration

Conditions studied

Thymus Carcinoma — all drugs for Thymus Carcinoma →

Sponsor

Jonsson Comprehensive Cancer Center — full company profile →

Who can join

18 and older, any sex, with Thymus Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase II trial tests how well ivonescimab works in treating patients with thymic carcinoma. Immunotherapy with monoclonal antibodies, such as ivonescimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Oncologic strategies and options for the management of metastatic thymic carcinoma.
Maniar R, Loehrer PJ. · · 2026 · PMID 41982608 · DOI 10.21037/med-25-38
Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy.
Canaslan K, Moeini Nia F, Baez M, Abolhassani H, et al · · 2026 · PMID 41843177 · DOI 10.1007/s00262-026-04311-4

Verify or expand the search:

Other trials of Biopsy Procedure

Trials testing the same drug.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07069699 — Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene · Phase 1, PHASE2 · recruiting
NCT06732388 — Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's E · Phase 2 · not yet recruiting

Other recruiting trials for Thymus Carcinoma

Currently open trials in the same condition.

NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting

Other Jonsson Comprehensive Cancer Center trials

Trials by the same sponsor.

NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
NCT07517211 — A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, · not yet recruiting
NCT07191717 — Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Resi · Phase 2 · not yet recruiting
NCT07468903 — Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06980077 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center
Last refreshed: 20 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06980077.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing